In Silico ADMET Profiling and Drug-Likeness Evaluation of Novel Thiopyrano[2,3-d]thiazole Derivatives as Potential Anticonvulsants
Scientia Pharmaceutica · 09.04.2026 · 94 (2) · 30
DOI: 10.3390/scipharm94020030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientia Pharmaceutica, online erschienen am 09.04.2026. Verfasst von Maryna Stasevych und 5 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education and Science.
Abstract (Originalsprache)
The development of novel antiepileptic agents requires early identification of pharmacokinetic limitations to mitigate risks at later stages. This study aimed to perform in silico profiling of a library containing 448 novel 2H,5H-chromeno[4’,3’:4,5]thiopyrano[2,3-d]thiazol-2-one derivatives to select lead compounds with an optimal balance of safety and efficacy. The study was conducted using the ADMET-AI platform, based on a graph neural network, to predict physicochemical, pharmacokinetic, and toxicological properties. The methodology involved calculating drug-likeness descriptors for primary screening and a comparative statistical analysis of the top 20 selected structures against 16 approved antiepileptic drugs and four reference compounds. Based on drug-likeness descriptors and predicted ADMET (absorption, distribution, metabolism, excretion, toxicity) related parameters, 20 structures were prioritized for further analysis. Their predicted profiles suggested high intestinal absorption and blood–brain barrier (BBB) permeability, which may be relevant for central nervous system (CNS) directed agents. In comparison with the reference thiazolidinones, the prioritized compounds showed comparatively more favorable predicted mutagenicity and carcinogenicity profiles. Elevated predicted risks of hepatotoxicity and cardiotoxicity were observed for several structures, indicating the need for further structural optimization. The results suggest that the thiopyranothiazolidinone scaffold merits further anticonvulsant-oriented investigation at the stage of early compound prioritization. Experimental validation will be required to confirm the actual pharmacokinetic, toxicological, and anticonvulsant properties of the prioritized compounds.
Förderung
- Ministry of Education and Science
Zitieren
APA
Stasevych, M., Hoidyk, M., Zvarych, V., Karkhut, A., Polovkovych, S., & Lesyk, R. (2026). In Silico ADMET Profiling and Drug-Likeness Evaluation of Novel Thiopyrano[2,3-d]thiazole Derivatives as Potential Anticonvulsants. Scientia Pharmaceutica, 94(2), 30. https://doi.org/10.3390/scipharm94020030
Vancouver
Stasevych M, Hoidyk M, Zvarych V, Karkhut A, Polovkovych S, Lesyk R. In Silico ADMET Profiling and Drug-Likeness Evaluation of Novel Thiopyrano[2,3-d]thiazole Derivatives as Potential Anticonvulsants. Scientia Pharmaceutica. 2026;94(2):30. doi:10.3390/scipharm94020030
BibTeX
@article{Stasevych2026,
author = {Stasevych, Maryna and Hoidyk, Mykhailo and Zvarych, Viktor and Karkhut, Andriy and Polovkovych, Svyatoslav and Lesyk, Roman},
title = {In Silico ADMET Profiling and Drug-Likeness Evaluation of Novel Thiopyrano[2,3-d]thiazole Derivatives as Potential Anticonvulsants},
journal = {Scientia Pharmaceutica},
year = {2026},
volume = {94},
number = {2},
pages = {30},
doi = {10.3390/scipharm94020030}
}
EUVIMED